Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716428 · ClinicalTrials.gov registry record · Phase 2
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
A Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV), sponsored by Trek Therapeutics, PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 6
- Study locations
NCT02716428 is a Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV) that has completed, run by Trek Therapeutics, PBC. The registered enrollment target is 25 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT02716428, a Phase 2 study of Chronic Hepatitis C and Hepatitis C (HCV), has completed, sponsored by Trek Therapeutics, PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG TD-6450
- DRUG Faldaprevir
Study Locations (6)
Other
- Auckland Clinical Studies - Auckland
- Dunedin Hospital - Dunedin
- Waikato Hospital - Waikato
California
- Southern California Research Center - Coronado
Florida
- Bach and Godofsky Infectious Diseases - Bradenton
Tennessee
- Gastro One - Germantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716428
The ClinicalTrials.gov registry entry for NCT02716428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (88% lower). The listed sponsor is Trek Therapeutics, PBC, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Chronic Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT02716428 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02716428 about?
NCT02716428 is a clinical study titled "A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection". Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.
What is the current status of trial NCT02716428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-05. Estimated completion is 2017-09.
What conditions does trial NCT02716428 study?
This clinical trial studies the following conditions: Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Viral Infection, Hepatitis C Genotype 1.
What interventions are being tested in trial NCT02716428?
The interventions under investigation include: Ribavirin (DRUG), TD-6450 (DRUG), Faldaprevir (DRUG).
Who is sponsoring clinical trial NCT02716428?
This trial is sponsored by Trek Therapeutics, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02716428 being conducted?
This trial has 6 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
-
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
COMPLETED · Phase 2
-
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
COMPLETED · Phase 2
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.